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Effects of the Timolol-Dorzolamide Fixed Combination
and Latanoprost on Circadian Diastolic Ocular
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Anastasios G. P. Konstas4
PURPOSE. To evaluate the effect of the timolol-dorzolamide
fixed combination (TDFC) and latanoprost 0.005% on 24-hour
intraocular pressure (IOP), systolic (SBP) and diastolic (DBP)
blood pressure, and diastolic ocular perfusion pressure (DOPP)
in patients with primary open-angle glaucoma (POAG).
METHODS. This was an institutional, randomized clinical trial.
After a 24-hour assessment without treatment, 27 previously
untreated patients with POAG were randomized to 6 weeks’
treatment with twice-daily TDFC (8 AM and 8 PM) followed by
once-daily latanoprost 0.005% (8 PM), or vice versa. One eye
was analyzed per patient. The mean values of IOP, DBP, SBP,
and DOPP (difference between DBP and IOP) were recorded at
each time point, and the 24-hour data are the mean values of
each patient’s measurements over the 24-hour period. The
differences between the values of the first treatment period
and the baseline and the second treatment period and washout
were calculated and analyzed by means of an analysis of vari-
ance model that tested the effects of sequence and treatment.
RESULTS. Both treatments significantly reduced 24-hour IOP
(P ! 0.0001), but TDFC led to lower 24-hour pressure
(mean " SD: 15.4 " 1.9 vs. 16.7 " 1.7 mm Hg; P # 0.004).
Latanoprost did not lead to any significant reduction in mean
24-hour SBP and DBP (SBP: P # 0.952; DBP: P # 0.831), but
TDFC did (SBP and DBP: P ! 0.0001). Both treatments signif-
icantly increased 24-hour DOPP (P ! 0.0001), with no differ-
ence between the two medications (P # 0.09).
CONCLUSIONS. In previously untreated patients with POAG, TDFC,
and latanoprost equally enhanced 24-hour DOPP: the former by
counteracting the decrease in DBP with a substantial reduction in
IOP and the latter by not affecting DBP and significantly reducing
IOP. (isrctn.org number, ISRCTN67123277.) (Invest Ophthalmol
Vis Sci. 2008;49:4226–4231) DOI:10.1167/iovs.08-1744
Reducing intraocular pressure (IOP) is currently the goldstandard of primary open-angle glaucoma (POAG) ther-
apy,1–4 even though high IOP is not the only risk factor
involved in the pathogenesis of the disease.5
Several population-based epidemiologic studies have shown
that low diastolic blood pressure (DBP) and a diastolic ocular
perfusion pressure (DOPP) of !50 to 55 mm Hg are closely
associated with the prevalence6–9 and incidence10 of POAG,
and it has recently been reported that low blood pressure (BP)
is also a risk factor for progression of glaucoma.11 It therefore
seems reasonable that medical treatment for POAG should
lower IOP without decreasing DOPP, which may be induced
by an insufficient reduction in IOP or a decrease in BP.
However, there is little available information concerning
the potential effects of current medical therapy on DOPP,
particularly its effect on 24-hour IOP and BP patterns. The only
study investigating the 24-hour curve of IOP and DOPP in
patients with glaucoma12 found that latanoprost induced a
fairly uniform reduction in IOP and a concomitant increase in
DOPP over 24 hours, whereas dorzolamide reduced IOP to a
lesser extent, although the increase in DOPP was not signifi-
cantly different from that induced by latanoprost. Timolol and
brimonidine significantly reduced 24-hour IOP, but did not
significantly increase 24-hour DOPP, which was explained as
being mainly a secondary effect of both on BP.
In the light of these results, it was interesting to assess
the efficacy of the timolol–dorzolamide fixed combination
(TDFC), as the concomitant presence of both drugs should not
only significantly reduce IOP, but should also affect DOPP.
TDFC has already been extensively investigated, but most stud-
ies have evaluated its effect on office IOP,13–16 and only two
have evaluated its effect on 24-hour IOP in patients with
POAG, finding that it was substantially equivalent to that of
latanoprost.17,18
The purpose of this study was to compare the effects of
TDFC and latanoprost (which has been shown to increase
DOPP12) on 24-hour IOP, BP, and DOPP profiles in a selected
population of newly diagnosed and previously untreated pa-
tients with POAG, who were unaffected by or being treated for
systemic hypertension as hypertension and its treatment may
unpredictably affect 24-hour BP19 and interfere with the reduc-
tion in IOP induced by timolol.20
METHODS
The study involved 27 consecutive, newly diagnosed, previously un-
treated patients with POAG $45 years of age with no history of eye
surgery or laser treatment, who attended the Glaucoma Service of the
University of Brescia, Italy. The inclusion criteria were open angle by
gonioscopy (grade III–IV according to Shaffer’s grading system); an
untreated diurnal IOP of 22 to 32 mm Hg (mean of the two highest
values recorded on a daytime IOP curve of measurements made every
2 hours between 8 AM and 6 PM, using a calibrated Goldmann appla-
nation tonometer), as assessed by means of two IOP trials repeated on
two different days (1 week apart); an optic disc with diffused/localized
thinning of the neuroretinal rim and/or diffused/localized increase in
cupping; a visual acuity of 20/40 or better; a mean deviation of !%6
dB (Humphrey 24-2 program, Humphrey Visual Field Analyzer Model
745; Carl Zeiss S.p.A, Arese, Italy), confirmed by two consecutive
measurements; no history of allergy to the ingredients of any of the
study drugs; no history of cardiovascular disease (e.g., arterial hyper-
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tension, heart disease, and arrhythmia), and no concomitant systemic
treatment that may modify BP (!-blockers, angiotensin-converting en-
zyme inhibitors, calcium channel blockers, and diuretics). Women
were enrolled only if they were postmenopausal or were using con-
traceptives.
The study protocol adhered to the tenets of the Declaration of
Helsinki and was approved by the local institutional review board (IRB;
Clinica Oculistica, University of Brescia). Informed consent was ob-
tained from all participants.
The enrolled patients underwent 24-hour IOP and ambulatory BP
monitoring during a 3-day hospitalization period. IOP was measured
every 2 hours by using a calibrated Goldmann applanation tonometer
(GAT; Haag-Streit, Bern, Switzerland) to measure sitting IOP at the slit
lamp between 8 AM and 10 PM and a calibrated handheld electronic
tonometer (TonoPen XL; BioRad, Glendale, CA) to measure supine IOP
between 12 and 6 AM with the patient in bed. The mean of three
consecutive readings was calculated for each time point. IOP measure-
ments were made by three well-trained observers who were unaware
of the treatment assignments. Their agreement was tested in a pilot
sample of 15 patients, which led to an intraclass correlation coefficient
of 0.97 for handheld tonometry and 0.99 for Goldmann tonometry.
Ambulatory BP was recorded by means of an automated portable
TM-2430 (A&D Co., Saitama, Japan), which indirectly measured BP by
means of the oscillometric measurement of the vibratory signals asso-
ciated with blood flow in the brachial artery. The device satisfies the
systolic and diastolic BP accuracy levels recommended by the British
Hypertension Society and the Association for Advancement of Medical
Instrumentation.21 A cuff of appropriate size was placed on the sub-
ject’s nondominant arm, and BP was measured automatically every 15
minutes between 8 AM and 10 PM and every 30 minutes between 10
PM and 8 AM. If a reading was not performed properly, the device was
programmed to repeat it. The BP values recorded throughout the
24-hour period were subsequently recovered from the recording chip
and stored on a personal computer.
Hospital 24-hour BP and IOP were monitored on separate days to
prevent the IOP measurement process from affecting the BP readings.
The study had a randomized, blinded observer, two-treatment, and
two-period crossover design. After the baseline IOP and BP measure-
ments had been recorded, the patients were randomly assigned to one
of the two treatment sequences (TDFC–latanoprost; latanoprost–
TDFC), and prescribed 1 drop of TDFC twice daily (at 8 AM and 8 PM)
or 1 drop of latanoprost once daily (at 10 PM). The 6-week treatment
periods were separated by a 4-week washout period. The subsequent
24-hour IOP and BP measurements were made at baseline, at the end
of the first treatment period, after the 4-week washout period (second
baseline), and at the end of the second treatment period.
At baseline, the patients were hospitalized in the afternoon of day
1. The first IOP measurement was made at 8 AM on day 2 and then
every 2 hours as described earlier. The last IOP measurement was
made at 6 AM on day 3. After this last IOP measurement, the patients
were fitted with the dynamic BP measuring device, which was kept in
place for 24 hours (until 7 AM on day 4).
At the end of the first treatment period, the patients were hospi-
talized in the afternoon of day 1, and TDFC or latanoprost were
administered at 8 PM by the dosing coordinator of the study. The first
IOP measurement was made at 8 AM on day 2 (just before the morning
instillation of TDFC at 8 AM) and then every 2 hours as described
above; the last IOP measurement was made at 6 AM on day 3. After this
last IOP measurement, the patients were fitted with the dynamic BP
measuring device, which was kept in place for 24 hours (until 7 AM on
day 4); during BP monitoring, the study drugs were administered as
described earlier.
The same procedures were then repeated at the end of the washout
period and at the end of the second treatment period.
The patients underwent a complete ocular and systemic examina-
tion at baseline and at the end of each phase of the trial, and all ocular
or systemic adverse events were recorded.
One eye was analyzed per patient. If both eyes were eligible, one
was randomly selected for statistical analysis. The mean " SD of IOP,
DBP, SBP, and DOPP (calculated as the difference between DBP and
IOP) were recorded at each time point, and the 24-hour data are the
mean of each patient’s measurements over the 24-hour period. The
differences between the values in each treatment period and the
baseline or washout values were calculated and analyzed by means of
an analysis of variance model that tested the effects of sequence and
treatment, and the same analysis was also applied separately to the day
(from 8 AM to 10 PM) and night (from 12 to 6 AM) glaucoma.
The sample size provided a 90% power to detect a standardized
effect size in 24-hour IOP and 24-hour DOPP of at least 0.65 at a
significance level of 0.05 for a two-sided test. According to Cohen,22
such an effect size corresponds to a medium-high effect.
The analyses were made using SAS software (Statistical Analysis
System, ver. 9.0; SAS Institute Inc., Cary, NC). Data are expressed as the
mean (SD).
RESULTS
All 27 enrolled patients completed all the study phases, during
which no serious adverse events were observed. Table 1 shows
the descriptive statistics of the patients. To keep a logical
sequence, IOP- and BP-related results are reported first, as they
are the basis for DOPP calculation. There were no significant
differences in IOP or BP between the baseline values and those
obtained after the washout period, thus suggesting the absence
of any carryover effect.
Intraocular Pressure
Mean 24-hour IOP was 22.9 " 3.2 mm Hg at baseline, 22.7"
2.9 mm Hg at the end of the washout period, 15.4 " 1.9 mm
Hg after TDFC, and 16.7 " 1.7 mm Hg after latanoprost. Both
therapies significantly reduced IOP in comparison with base-
line (P ! 0.0001). The observed reduction was %7.4 mm Hg
(95% CI: %7.8 to %6.9) with TDFC, and %6.1 mm Hg (95% CI:
%6.5 to%5.6) with latanoprost, with a significant difference in
treatment effect in favor of TDFC (%1.3 mm Hg [95% CI: %1.5
to %1.1]; P ! 0.0001) (Table 2). Analysis of variance of the
differences in comparison with baseline showed no treatment
sequence effect (P # 0.331).
The reduction from baseline during the day was greater
with TDFC than with latanoprost (%7.7 mm Hg [95% CI: %8.2
to %7.1] vs. %6.5 mm Hg [95% CI: %7.0 to %5.9]); the differ-
ence between treatments (%1.2 mm Hg [95% CI: %1.7 to
%0.8]) was statistically significant (P ! 0.0001). The reduction
from baseline during the night was also greater with TDFC
(%6.7 mm Hg [95% CI:%7.3 to%6.0] vs.%5.3 mm Hg [95% CI:
%5.8 to%4.8]), and the between-treatment difference was also
statistically significant (%1.4 mm Hg [95% CI: %2.1 to %1.6];
P # 0.001).
Systolic Blood Pressure
Mean 24-hour SBP was 125.0 (4.5) mm Hg at baseline, 125.0
(4.4) mm Hg at the end of the washout period, 122.0 (4.2) mm
Hg after TDFC, and 125.0 (4.4) mm Hg after latanoprost.
TABLE 1. Patients’ Characteristics
Patients (n) 27
Age, y* 61 (4.5)
Male, n (%) 11 (40.7)
Baseline IOP (SD), mm Hg* 25.4 (2.6)
Baseline SBP (SD), mm Hg* 124.3 (4.6)
Baseline DBP (SD), mm Hg* 74.2 (5.4)
* Mean (SD).
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Latanoprost had no significant effect (%0.01 mm Hg [95% CI:
%0.2 to 0.1]; P # 0.463), whereas the effect of TDFC was
statistically significant (%3.1 mm Hg [95% CI: %3.3 to %2.8];
P ! 0.0001); the between-treatment difference was also statis-
tically significant (%3.0 mm Hg [95% CI: %3.3 to %2.8]; P !
0.0001; Fig. 1). Analysis of variance of the differences in com-
parison with baseline showed no treatment sequence effect
(P # 0.208).
The reduction from baseline during the day was greater
with TDFC than with latanoprost (%3.2 mm Hg [95% CI: %3.5
to %2.8] vs. %0.1 mm Hg [95% CI: %0.3 to 0.2]), and the
difference between treatments was statistically significant
(%3.1 mm Hg [95% CI: %3.4 to %2.8]; P ! 0.0001). The
reduction from baseline during the night was also greater with
TDFC (%2.9 mm Hg [95% CI: %3.3 to %2.5] vs. %0.1 mm Hg
[95% CI: %0.4 to 0.3]), and the between-treatment difference
was also statistically significant (%2.8 mm Hg [95% CI: %3.2 to
%2.4]; P ! 0.0001).
Diastolic Blood Pressure
Mean 24-hour DBP was 73.5 (5.2) mm Hg at baseline, 73.3 (5.2)
mm Hg at the end of the washout period, 71.6 (5.2) mm Hg
after TDFC, and 73.6 (5.0) mm Hg after latanoprost. Latano-
prost had no significant effect (%0.3 mm Hg [95% CI: %0.0 to
0.6]; P # 0.414), but that of TDFC was statistically significant
(%1.9 mm Hg [95% CI: %2.2 to %1.6]; P ! 0.0001), and the
difference between treatments was statistically significant
(%2.0 mm Hg [95% CI: %2.2 to %1.8]; P ! 0.0001; Fig. 2).
Analysis of variance of the differences in comparison with
baseline showed no treatment sequence effect (P # 0.928).
The reduction from baseline during the day was greater
with TDFC than with latanoprost (%2.2 mm Hg [95% CI: %2.5
to %2.8] vs. 0.3 mm Hg [95% CI: %0.1 to 0.6]), and the
difference was statistically significant (%2.4 mm Hg [95% CI:
%2.8 to %2.1]; P ! 0.0001). The reduction from baseline
during the night was also greater with TDFC (%1.4 mm Hg
[95% CI:%1.8 to%0.9] vs. 0.4 mm Hg [95% CI: 0.0 to 0.8), and
the difference was statistically significant (%1.8 mm Hg [95%
CI: %2.4 to %1.1]; P ! 0.0001).
Diastolic Ocular Perfusion Pressure
Mean 24-hour DOPP was 50.4 (6.7) mm Hg at baseline, 50.3
(6.5) mm Hg at the end of the washout period, 56.4 (5.9) mm
Hg after TDFC, and 56.7 (5.7) mm Hg after latanoprost (Table
3). Both therapies significantly increased DOPP in comparison
with baseline (P ! 0.0001).
The increase from baseline was 5.9 mm Hg (95% CI: 5.3 to
6.5) with TDFC, and 6.5 mm Hg (95% CI: 5.8 to 7.1) with
latanoprost, a difference that was not statistically significant
TABLE 2. Intraocular Pressure by Study Phases
Time Baseline Washout TDCF Latanoprost
8 AM 26.5 (1.78) 26.4 (1.62) 17.2 (1.40) 18.7 (1.07)
10 AM 26.4 (1.87) 26.8 (1.95) 16.7 (1.70) 17.2 (1.62)
Noon 25.4 (1.88) 25.1 (1.80) 15.5 (1.31) 17.4 (1.25)
2 PM 22.3 (2.78) 21.7 (1.70) 14.7 (2.06) 15.4 (1.65)
4 PM 21.2 (2.85) 21.6 (1.62) 14.8 (1.40) 16.7 (1.51)
6 PM 21.4 (2.59) 21.3 (2.05) 15.0 (2.18) 16.1 (1.50)
8 PM 20.4 (2.53) 20.3 (1.94) 14.4 (1.39) 16.0 (1.65)
10 PM 20.7 (2.03) 20.1 (1.29) 13.4 (1.40) 15.0 (1.87)
Midnight* 20.0 (2.42) 19.9 (1.68) 14.4 (1.95) 16.6 (1.72)
2 AM* 21.2 (2.22) 21.2 (1.32) 15.8 (1.51) 17.0 (1.74)
4 AM* 23.7 (2.20) 23.8 (1.60) 16.4 (1.11) 17.4 (1.53)
6 AM* 25.1 (1.82) 24.5 (1.76) 16.7 (1.14) 17.0 (1.02)
24-hour IOP 22.9 (3.22) 22.7 (2.90) 15.4 (1.91) 16.7 (1.72)
Data are expressed as the mean (SD).
* Data were obtained in participants in the supine/recumbent
body position.
FIGURE 1. Dynamic SBP by study phase.
FIGURE 2. Dynamic DBP by study phase.
TABLE 3. Diastolic Ocular Perfusion Pressure by Study Phases
Time Baseline Washout TDCF Latanoprost
8 AM 47.4 (3.32) 47.4 (2.96) 55.6 (2.32) 55.9 (2.48)
10 AM 46.7 (3.98) 46.3 (3.10) 54.9 (3.16) 56.0 (2.47)
Noon 50.8 (3.24) 51.0 (3.92) 59.7 (2.09) 59.5 (2.01)
2 PM 52.0 (4.24) 53.2 (3.04) 57.8 (3.53) 58.4 (2.36)
4 PM 56.8 (4.06) 55.9 (2.71) 61.1 (2.10) 61.2 (2.46)
6 PM 57.7 (3.76) 57.3 (2.46) 61.9 (2.95) 62.7 (2.49)
8 PM 57.1 (3.53) 57.5 (2.82) 62.5 (2.03) 62.0 (1.70)
10 PM 57.2 (2.76) 57.2 (2.78) 62.4 (2.36) 62.8 (2.80)
Midnight* 51.2 (3.82) 50.6 (2.66) 55.8 (2.39) 55.2 (2.71)
2 AM* 45.5 (3.46) 44.9 (2.52) 49.7 (2.18) 49.4 (2.31)
4 AM* 39.6 (2.76) 39.0 (2.27) 45.6 (2.22) 46.4 (2.19)
6 AM* 42.8 (2.59) 43.6 (2.65) 50.0 (1.83) 50.9 (2.11)
24-hour DOPP 50.4 (6.78) 50.3 (6.53) 56.4 (5.95) 56.7 (5.74)
Data are expressed as the mean (SD). DOPP diastolic ocular
perfusion pressure.
* Data were obtained in supine/recumbent body position; refer to
the text for appropriate interpretation.
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(0.5 [95% CI: %0.1 to 1.2]; P # 0.09). Analysis of variance
showed no effect of treatment sequence (P # 0.331).
The increase from baseline during the day was greater with
latanoprost than with TDFC (6.8 mm Hg [95% CI: 6.0 to 7.6] vs.
6.0 mm Hg [95% CI: 5.3 to 6.8]), and the difference between
treatments was statistically significant (%0.8 mm Hg [95% CI:
%1.6 to 0.0]; P# 0.049). The increase from baseline during the
night was similar with TDFC and latanoprost (5.7 mm Hg [95%
CI: 5.0 to 6.4] vs. 5.7 mm Hg [95% CI: 5.0 to 6.5]), and the
between-treatment difference was not statistically significant
(%0.02 mm Hg [95% CI: %1.0 to 1.0]; P # 0.970).
DISCUSSION
In comparison with no treatment, both TDFC and latanoprost
significantly reduced 24-hour IOP in this group of newly diag-
nosed and previously untreated patients with POAG who did
not have or who were being treated for systemic hypertension.
TDFC reduced IOP to a significantly greater extent than did
latanoprost and, unlike latanoprost, significantly reduced 24-
hour BP in comparison with baseline. DOPP was significantly
increased by both treatments at all time points, with no signif-
icant difference between them.
TDFC reduced IOP to a significantly greater extent than
latanoprost in comparison with the findings of other 24-hour
investigations: Konstas et al.17 found a 0.6 mm Hg advantage
for TDFC, Orzalesi et al.18 found a 0.2-mm Hg advantage for
latanoprost, and we found a 1.3-mm Hg advantage for TDFC. It
should be noted that the study of Orzalesi et al.18 may have
been affected by a selection bias, in that 13 of the 20 patients
had systemic hypertension treated with systemic !-blockers (6
patients) or other unspecified medications (7 patients), which
may have decreased the ocular hypotensive efficacy of timo-
lol.20 All the patients in our study had POAG but no cardiovas-
cular diseases (e.g., hypertension, cardiac insufficiency, ar-
rhythmia), and none of them was taking any systemic
medication that could modify BP or interfere with the hypo-
tensive effects of timolol.
The difference between our findings and those of Konstas
et al.17 may be partially attributable to the fact that our newly
diagnosed and untreated patients may have been more respon-
sive to timolol than were patients previously treated with
!-blockers23 (11/33 patients in Konstas et al.17).
Latanoprost induced a uniform IOP reduction for 24 hours,
but its hypotensive effect was greater during the day and 12
hours after administration, as found in previous studies.23–29
The statistically significant difference in the effects of TDFC
and latanoprost observed in our study was not found in several
previous studies of much larger patient samples.30–35 How-
ever, all these were based on single office or only daytime IOP
measurements and did not have high BP and its treatment as
exclusion criteria. Moreover, they all included previously
treated patients or patients in whom !-blockers had failed to
provide clinically acceptable control of IOP. Taken together, all
these factors may have contributed to the different findings of
these studies.
In line with the findings of previous studies,12 we found
that latanoprost did not have any effect on 24-hour SBP or DBP,
whereas TDFC reduced both, thus confirming the results of
previous investigations showing that topically applied !-block-
ers reduce systemic BP.12,16,36–40
Given their effects on BP and IOP, both TDFC and latano-
prost significantly increased DOPP at all time points, without
any significant between-treatment difference in mean 24-hour
DOPP values. Despite the significant reduction in BP, possibly
due to the effect of timolol on BP,12,36–40 TDFC induced a
significant increase in DOPP at all time points because of the
concomitant significant reduction in IOP, which may be ex-
plained by the relevant effect of dorzolamide on IOP at
night.12,24,41–43
Several limitations should be taken into account when in-
terpreting the findings of this study. First of all, the sample size
was small, although the study’s crossover design had sufficient
statistical power to assess any differences between the two
regimens. Nevertheless, the comparison concerning DOPP
may have been underpowered. Second, the population was
highly selective because systemic hypertension is very fre-
quent in the age group of patients with POAG, and our results
cannot be generalized to the overall POAG population. How-
ever, systemic hypertension and its treatment were considered
exclusion criteria because of their potential effect on BP due to
the greater variability in BP in patients treated with systemic
antihypertensive medications,19 and the possibly negative im-
pact of antihypertensive medications (such as systemic
!-blockers) on the hypotensive effect of timolol.20 Third, the
study was only observer masked and should have been per-
formed in a double-masked fashion to minimize any potential
bias. However, this was an investigator-initiated trial, and ap-
propriate double masking was not feasible. Fourth, perfusion
pressure has been calculated by subtracting the IOP from the
BP. This formula is not fully compatible with the widely used
formula for the calculation of OPP [mean BP ! (2/3) % IOP],
which better considers the physiological pressure difference
between the brachial BP and the BP close to the eyeball.
Nevertheless, the DOPP, as calculated in the present study, has
been found to be associated with glaucoma in several epide-
miologic investigations6–10 and is probably a reasonable surro-
gate for the OPP when the patient is awake and in a vertical
body position. Although It is well known that the relationship
between OPP and systemic BP in a recumbent body position
(nighttime) is different from that in a vertical body position
(daytime),44 it is difficult to discuss any physiological implica-
tion that could be related to the different impact of OPP during
day- and nighttime. Finally, the use of a handheld tonometer
(TonoPen; Bio-Rad) rather than GAT for measurement of noc-
turnal IOP may be a concern, as there is no close agreement
between the two procedures.45 However, it did allow us to
make the nighttime IOP and BP measurements with the pa-
tients in bed and supine (which may better reflect real-life
conditions), thus minimally disturbing the patients and avoid-
ing the physiological changes in BP and IOP that occur when
they rise from a supine to a standing position.46 Furthermore,
the fair agreement between GAT and tonometer IOP measure-
ments should not be considered a major problem as the study
design allowed the comparison of paired measurements always
made at the same time: This may require a certain caution in
interpreting the accuracy of the nocturnal IOP measurements,
but should not have any impact on comparisons of the night-
time measurements in individual patients.
It remains to be demonstrated whether DOPP may be con-
sidered an accurate marker in the management of POAG but, as
the bulk of epidemiologic and clinical evidence strongly sup-
ports considering daytime BP and DOPP as relevant elements
in the multifactorial pathogenesis of POAG6–10 and possibly its
progression,11 it may be clinically important to assess them in
patients with treated POAG. We found that both TDFC and
latanoprost increased mean 24-hour DOPP, and DOPP at all
time points from 8 AM to 8 PM, to $50 mm Hg (above the
daytime threshold that has been shown to represent a risk for
the development of POAG6–8,10), the former by counteracting
the expected decrease in DBP with a considerable reduction in
IOP, and the latter by not affecting DBP and significantly
reducing IOP.
However, given the short follow-up time in this study and
the relatively small sample size, our results should be inter-
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preted cautiously. Further investigations are needed to estab-
lish the long-term effects of these treatments on BP and DOPP
profiles.
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